Summary
This document is a technical report detailing the AVENIO Tumor Tissue CGP Kit Version 2, which has been launched by Roche to enhance cancer research capabilities. The report outlines the features and improvements of the new kit compared to its predecessor, the AVENIO Tumor Tissue CGP Kit Version 1. It describes the comprehensive panel content, which now includes 335 relevant genes and various genomic alterations, along with the addition of a new complex biomarker, the pan-tumor HRD signature. The report also presents the optimized workflows that facilitate a faster turnaround time from DNA extraction to result generation, highlighting the efficiency of the updated bioinformatics algorithms. Furthermore, it documents the strong agreement in analytical performance between the two versions of the kit, emphasizing the improvements in variant detection and the overall reliability of the AVENIO Tumor Tissue CGP Kit V2 for research use. The report is intended for research purposes only and is not for diagnostic procedures.
